– GERMANY, Munich – Ebenbuild, a company developing personalized, AI-enabled digital twins of lungs to support clinical decisions and digital clinical trials, announced the appointment of Dr. Charles Taylor (Ph.D.) as Chairman of the Board of Directors.
About Dr. Charles A. Taylor
Dr. Taylor is a pioneer in the field of predictive, simulation-based medicine where he applied computational fluid dynamics to predict outcomes of cardiovascular interventions in individual patients.
“I am very impressed with Ebenbuild’s work in developing patient-specific computer models of the lungs. I believe that Ebenbuild will revolutionize the diagnosis and treatment of respiratory diseases,” said Dr. Taylor, Ebenbuild’s Chairman. “I look forward to working very closely with the Ebenbuild team on their financing, business development and regulatory activities to define a clear path to market and achieve sustainable corporate growth.”
Dr. Taylor is a founder of HeartFlow, Inc., and a member of its Board of Directors. He served as CTO and then CSO at HeartFlow where he focused on technology innovation, driving research and development, and advancing the product to commercialization. He is also an Adjunct Professor of Computational Engineering and Sciences at the University of Texas, Austin, TX, and a part-time Professor of Biomedical Engineering at the Technical University of Eindhoven. Before founding HeartFlow, he was an Associate Professor in the Department of Bioengineering and Surgery at Stanford University, where he focused on the development of computational modeling and imaging techniques for improving the diagnosis and management of cardiovascular disease.
Dr. Taylor has authored more than 450 peer-reviewed publications and holds over 300 issued U.S. and international patents. He has been a Fellow of the American Institute for Medical and Biological Engineering (AIMBE) since 2007 and was elected to the National Academy of Engineering in 2024.
Dr. Charles Taylor received his B.S. degree in Mechanical Engineering, M.S. degree in Mechanical Engineering M.S. degree in Mathematics from Rensselaer Polytechnic Institute, and a Ph.D. in Mechanical Engineering from Stanford University.
About Ebenbuild
Ebenbuild is a digital health tech pioneer developing precise computer models of lungs based on patient-specific data, i.e. digital twins of the lungs. Its digital toolset is based on physics-based simulation, AI, and data science and is designed to support decision-makers in the life sciences and healthcare industries. Ebenbuild technology deepens the understanding of respiratory diseases and individual pathophysiology. It enables products ranging from personalized decision support to improve patient outcomes in severe respiratory diseases to in silico trials to accelerate and de-risk the development of inhaled drugs.
Ebenbuild develops personalized lung simulation models based on patient-specific data with broad application to chronic and acute lung diseases. The first application of Ebenbuild’s digital lung twins aims to improve treatment outcomes in ICU patients who suffer from life-threatening lung complications such as Acute Lung Injury/Acute Respiratory Distress Syndrome (ALI/ARDS), which has a mortality rate of 40%. These lung complications make breathing extremely arduous and strongly impair gas exchange. Despite advances in diagnosis and intensive care, ALI/ARDS remains underdiagnosed and undertreated, making it a major global health problem.
For more information: https://www.ebenbuild.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.